Stock 6518 CONCORD MEDICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Concord Medical Co., Ltd.

Equities

6518

TW0006518004

Pharmaceuticals

End-of-day quote Taipei Exchange
Other stock markets
 23:00:00 23/05/2024 BST 		5-day change 1st Jan Change
26.4 TWD -0.56% Intraday chart for Concord Medical Co., Ltd. -0.38% +3.12%
03-07 Concord Medical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Concord Medical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 297.2 356 350 450 786.7 853.3
Enterprise Value (EV) 1 407.4 637.2 609.9 441.4 620.7 739.7
P/E ratio 19.5 x 11.4 x 17.7 x 13.1 x 15.5 x 20 x
Yield 3.36% 2.81% 2.86% 2.78% 4.24% 3.91%
Capitalization / Revenue 0.42 x 0.47 x 0.43 x 0.61 x 0.88 x 1.02 x
EV / Revenue 0.58 x 0.83 x 0.75 x 0.6 x 0.7 x 0.89 x
EV / EBITDA 4.1 x 5.14 x 5.67 x 3.95 x 4.47 x 5.63 x
EV / FCF 10.1 x 8.01 x -52.2 x 3.66 x 5.7 x 45.7 x
FCF Yield 9.94% 12.5% -1.92% 27.3% 17.5% 2.19%
Price to Book 0.61 x 0.71 x 0.68 x 0.94 x 1.17 x 1.25 x
Nbr of stocks (in thousands) 25,000 25,000 25,000 25,000 33,333 33,333
Reference price 2 11.89 14.24 14.00 18.00 23.60 25.60
Announcement Date 30/04/19 22/04/20 31/03/21 16/03/22 09/03/23 07/03/24
1TWD in Million2TWD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 703 763.8 809.7 739 889.2 833.2
EBITDA 1 99.29 123.8 107.6 111.7 138.8 131.4
EBIT 1 20.45 41.91 28.1 37.3 64.78 54.74
Operating Margin 2.91% 5.49% 3.47% 5.05% 7.29% 6.57%
Earnings before Tax (EBT) 1 19.17 39.3 25.57 42.79 64.22 54.53
Net income 1 15.29 31.38 19.77 34.4 50.66 42.74
Net margin 2.18% 4.11% 2.44% 4.65% 5.7% 5.13%
EPS 2 0.6100 1.250 0.7900 1.370 1.520 1.280
Free Cash Flow 1 40.49 79.6 -11.68 120.4 108.8 16.19
FCF margin 5.76% 10.42% -1.44% 16.3% 12.24% 1.94%
FCF Conversion (EBITDA) 40.78% 64.27% - 107.85% 78.38% 12.32%
FCF Conversion (Net income) 264.76% 253.66% - 350.14% 214.81% 37.87%
Dividend per Share 2 0.4000 0.4000 0.4000 0.5000 1.000 1.000
Announcement Date 30/04/19 22/04/20 31/03/21 16/03/22 09/03/23 07/03/24
1TWD in Million2TWD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 110 281 260 - - -
Net Cash position 1 - - - 8.64 166 114
Leverage (Debt/EBITDA) 1.109 x 2.27 x 2.416 x - - -
Free Cash Flow 1 40.5 79.6 -11.7 120 109 16.2
ROE (net income / shareholders' equity) 3.18% 6.35% 3.89% 5.98% 7.51% 6.14%
ROA (Net income/ Total Assets) 1.44% 2.66% 1.6% 2.15% 3.59% 2.94%
Assets 1 1,061 1,178 1,236 1,602 1,413 1,454
Book Value Per Share 2 19.40 20.10 20.50 19.10 20.10 20.40
Cash Flow per Share 2 1.470 3.070 2.380 5.960 7.410 3.340
Capex 1 48.8 69.9 93.6 22.6 37.5 88.2
Capex / Sales 6.94% 9.16% 11.57% 3.06% 4.21% 10.58%
Announcement Date 30/04/19 22/04/20 31/03/21 16/03/22 09/03/23 07/03/24
1TWD in Million2TWD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
CONCORD MEDICAL CO., LTD. Stock Concord Medical Co., Ltd.
+3.12% 27.3M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+38.51% 727B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+33.05% 599B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.23% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.78% 328B
ABBVIE INC. Stock AbbVie Inc.
+1.35% 277B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.00% 243B
NOVARTIS AG Stock Novartis AG
+8.09% 205B
ROCHE HOLDING AG Stock Roche Holding AG
-5.77% 203B
AMGEN INC. Stock Amgen Inc.
+6.19% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 6518 Stock
  4. Financials Concord Medical Co., Ltd.